We have received a great number of enquiries for the latest information on wearable bolus (large volume) injectors, especially since our article “The Rise of the Bolus Injector” was published.
Therefore, Springboard’s Director of Drug Delivery Device Development, Tom Oakley has written a brand new article for OnDrugDelivery featuring the latest technical, commercial and regulatory developments in the world of bolus injectors.
Head over to OnDrugDelivery to read the latest news on bolus injectors, or read the whole edition devoted to large volume injectors.
Devices covered in the OnDrugDelivery magazine include:
- Unilife Precision-Therapy
- Sensile Medical SenseCore
- West SmartDose
- Enable Injections
- BD Libertas
- SteadyMed PatchPump
If you are from a pharmaceutical company or medical device developer and would like to find out more about bolus injectors and their development, please contact Tom Oakley on +44 (0) 1223 422 273.
Springboard has been featured in a new article about the demand for top medical device developers.
As a leading technology consultancy, Springboard excels in the development of devices for safety-regulated industries such as medical devices. These span drug delivery devices, diagnostics, minimally-invasive surgical tools, wound care and more.
See the full article at Business Weekly or, if you would like to get in touch now, call Tom Oakley on +44 (0) 1223 422 273.
Springboard’s Tom Oakley recently presented the latest developments of bolus (large volume) injectors at 2 major international conferences: the Management Forum in London and SMi America in New Jersey. Here is an update on the other hottest topics in injectable drug delivery… At the Management Forum, Amgen’s Mathias Romacker explained the trend to:
- Higher concentration formulations; and
- Larger doses with less frequent injections.
Interestingly, both of these trends point to an increased need for bolus injectors. 3P Innovation’s Tom Bailey and XstalBio’s Barry Moore showed the increased need for reconstitution devices, driven by the increased number of biologics being developed for subcutaneous delivery, especially therapeutic proteins. SHL’s Mats Persson described trends such as:
- Moving treatment from the hospital to the home for increased patient convenience and lower treatment cost;
- Using the injection device for drug product life-cycle management;
- Larger volume and higher viscosity injections required by new drug formulations;
- Increased emphasis by regulators on human factors studies;
- Interest in polymer, as opposed to glass, syringes;
- Autoinjectors for cartridges as opposed to syringes;
- Instructions for use on and in devices; and
- True end-of-dose indicators.
At the SMi America conference, Merck’s Scott Brown described the most common pitfalls of drug delivery device development, and Beroe’s Chanderkanth Gautam explained the opportunities and threats to electronic autoinjectors. In summary, developments in devices to inject drugs are being driven by:
- New biologics which may require larger injection volumes, higher viscosities, or reconstitution;
- Regulatory demands for human factors studies; and
- The need for increased adherence, which may be addressed by electronic functionality in devices.
If you work at a pharmaceutical company or medical device manufacturer and want to know more, please contact Tom Oakley.
The recent SMi conference on Pre-Filled Syringes brought together experts from the pharmaceuticals, manufacturing and materials industries to reveal and discuss the latest innovations and market trends for the important Pre-Filled Syringe sector.
The highlights were:
- The sources and types of leachables by Joel Richard of Ipsen
- Filling syringes will high concentration monoclonal antibodies by Yuh Fun Maa of Genentech
- Incorporating human factors and patient centric design by Alex Jaksch of BD
- Smart labelling by Thorsten Kircher of Schreiner MediPharm
The smart labelling presentation in particular showed some fascinating possibilities whereby labels could have RFID or NFC chips embedded, which can transmit information to a smartphone, for example redirecting it to a website.
If you wish to find out more about the latest developments in Pre-Filled Syringes, please feel free to contact Tom Oakley on +44 1223 422 273.
Springboard has been asked to present ‘The rise of the bolus injector‘ at the Management Forum on Injectable Drug Delivery.
We will build on a recent research project by the Cambridge University Judge Business School that Springboard sponsored.
The presentation will answer the most important questions for drug delivery professionals, such as:
- The changing needs of patients and new drugs
- Could autoinjectors and infusion pumps meet the needs?
- Bolus injectors: a new class of injection device
- Example devices
- What to expect from the draft standard ‘ISO 11608-6’ on bolus injectors
The Management Forum on Injectable Drug Delivery is one of the leading meetings of pharmaceutical and device professionals, and we highly recommend it to managers and executives working in pharmaceuticals, medical devices, clinical medicine, government, academia and patient support groups.
If you would like a face-to-face meeting at the event, please contact Springboard on +44 (0) 1223 422 273.
The presentation will be made available to Springboard’s current and potential clients after the congress so please get in touch if you are interested.
Tom Oakley, Director of Drug Delivery Device Development at Springboard, recently presented at the Management Forum Congress in London on ‘How devices can grow pharma profits‘.
The key challenges facing pharma were discussed, along with real-world examples of how devices can grow pharma profits by:
- Increasing drug value
- Giving extended patent protection to drugs
- Increasing the barrier to entry for generics and biosimilars
- Using existing drugs for new indications
- Increasing usability or addressing different user groups
- Changing the pharma company from a drug manufacturer to an integrated healthcare provider
Please contact Tom Oakley on +44 (0) 1223 422 273 if you represent a pharmaceutical or medical device company. We would be happy to run through the presentation with you.
The prestigious Judge Business School presented today their findings from a month-long research project on the market and leading technologies for ‘large volume’ or ‘bolus’ injections.
Springboard sponsored the research and provided industry expertise and contacts.
Tom Oakley, Director of Drug Delivery Device Development at Springboard said, ‘The Judge Business School team has approached the project with great professionalism and energy. They have been able to find very useful information on the new drugs which require large injections, and the market for bolus injectors.’
Many directors of device development and procurement at major pharmaceutical companies were interviewed by the team, and their requirements and predictions for the future have been analysed.
The report concludes with predictions of the potential market size, and an analysis of the strengths, weaknesses, opportunities and threats for bolus injectors.
Please contact Tom Oakley on +44 (0) 1223 422 273 if you represent a pharmaceutical or medical device company which requires bolus injector technology development. We would be happy to present the findings to you.
Tom Oakley, Director of Drug Delivery Device Development at Springboard, will be attending the Drug Delivery to the Lungs conference in Edinburgh from 11 to 13 December 2013.
As a leading contract developer of drug delivery devices, Springboard can provide turn-key device development, or fit in to an existing project to provide expertise such as:
- Technology scouting and due diligence
- Usability engineering
- Intellectual property navigation, freedom to operate and strategic development for IP
- Verification and validation plans and protocols
- Planning and management of the scale up to clinical trials and into production
Please contact Tom on +44 (0) 1223 422 273 if you would like to meet.
Springboard is attending the Drug Delivery to the Lungs conference in Edinburgh on 11 to 13 December 2013.
Drug Delivery to the Lungs is a leading conference and trade show for anyone interested in drug delivery to the airways.
The hot topics coming up in this year’s conference are:
- Inhaled nanomedicines
- Inhaled therapeutics for lung cancer
- Antibiotics delivered by inhalers
Springboard’s team of engineers and physicists has a convincing track record of developing inhalation devices and solving unexpected problems with them.
If you would like to meet us at the conference or any other time, please contact Tom Oakley, Director of Drug Delivery Device Development at Springboard.
Cambridge University’s prestigious Judge Business School has elected Springboard as their partner for a new research project into an exciting growth area of drug delivery devices.
The project will discover the growth opportunities for large volume injectors and will inform companies how to drive their technology strategy to maximise long-term commercial success.
The precise details will be revealed when the final report is made available in December.
The report will be made available to Springboard’s customers free of charge, and to others for a reasonable fee.
Please contact Tom Oakley if you would like to be notified when the project has been competed.